Skip to content
value.today

Aeterna Zentaris Inc.

Formerly Aeterna Laboratories Inc.

Aeterna Zentaris Inc. is listed today as COSCIENS Biopharma Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Aeterna Zentaris Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2020$5 MPrivate placement after listing$2 to $10 million

Aeterna Zentaris Inc.: Private sale, Feb 2020

Investors in this round

3 investors had bought by the notice of Mar 2, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$371,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Klaus Paulini · Executive Officer, Director
  • Leslie Auld · Executive Officer
  • Nicola Ammer · Executive Officer
  • Brent Norton · Director
  • Carolyn Egbert · Director
  • Gerard Limoges · Director
  • Gilles Gagnon · Director
  • Robin Smith Hoke · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NY

Remarks in the notice

  • On fees: “The commissions were based on gross proceeds of the registered direct offering of common shares that was concurrentwith the private placement of unregistered warrants and includes a management fee.”
  • On the amounts: “The issuer received gross proceeds of $4,500,000 from the issuance of 3,478,261 common shares in a registered directoffering and a concurrent private placement to purchase 0.75 common shares for each share purchased for cash in theoffering.”

Signed by Klaus Paulini, President and CEO. Source: SEC Form D, newest notice filed Mar 2, 2020. Read the notice at the SEC.

optionsSEC
Sep 2019$5 MPrivate placement after listing$2 to $10 million

Aeterna Zentaris Inc.: Private sale, Sep 2019

Investors in this round

4 investors had bought by the notice of Oct 1, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$349,125
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Canada (Federal Level)

People named in the notice

  • Klaus V. Paulini · Executive Officer
  • Leslie V. Auld · Executive Officer
  • Michael V. Ward · Executive Officer
  • Nicola V. Ammer · Executive Officer
  • Brent V. Norton · Director
  • Carolyn V. Egbert · Director
  • Gerard V. Limoges · Director
  • Robin V. Smith Hoke · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “The commissions were based on gross proceeds of the registered direct offering of common shares that was concurrent with the private placement of unregistered warrants.”
  • On the amounts: “The issuer received gross proceeds of $4,987,500 from the issuance of 3,325,000 common shares in a registered direct offering and a concurrent private placement of warrants to purchase up to 3,325,000 common shares.”

Signed by Michael V. Ward, President and CEO. Source: SEC Form D, newest notice filed Oct 1, 2019. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company COSCIENS Biopharma Inc., its revenue in fiscal 2025 came from these product and service lines: Active ingredients $7.04 million (94%), Biopharmaceutical $460,000 (6%).

    Annual report (SEC XBRL) · Dec 2025

  • Aeterna Zentaris Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2020

Products and services#

No products or services of Aeterna Zentaris Inc. are on record.

Investors#

No investor of Aeterna Zentaris Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aeterna Zentaris Inc.
NameRoleNamed in
Klaus PauliniExecutive officerMar 2020
Leslie AuldExecutive officerMar 2020
Nicola AmmerExecutive officerMar 2020
Klaus V. PauliniExecutive officerOct 2019
Leslie V. AuldExecutive officerOct 2019
Michael V. WardExecutive officerOct 2019
Nicola V. AmmerExecutive officerOct 2019
Brent NortonDirectorMar 2020
Carolyn EgbertDirectorMar 2020
Gerard LimogesDirectorMar 2020
Gilles GagnonDirectorMar 2020
Klaus PauliniDirectorMar 2020
Robin Smith HokeDirectorMar 2020
Brent V. NortonDirectorOct 2019
Carolyn V. EgbertDirectorOct 2019
Gerard V. LimogesDirectorOct 2019
Robin V. Smith HokeDirectorOct 2019

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.